Neuspera Medical Inc., a San Jose, Calif.-based clinical stage, private venture capital backed neuromodulation company, closed a $65m series C equity financing.
The round was co-led by Vertex Ventures HC and Treo Ventures with participation from returning Series A and Series B investors Action Potential Venture Capital and Windham Venture Partners. In conjunction with the funding, Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors.
The company intends to use the funds to conduct the SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).
Led by Milton M. Morris, Ph.D., President & CEO, Neuspera Medical is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronic medicines.
FinSMEs
21/07/2021